PL2590974T3 - Pochodne tetrahydropirydo-pirymidyny - Google Patents
Pochodne tetrahydropirydo-pirymidynyInfo
- Publication number
- PL2590974T3 PL2590974T3 PL11730637T PL11730637T PL2590974T3 PL 2590974 T3 PL2590974 T3 PL 2590974T3 PL 11730637 T PL11730637 T PL 11730637T PL 11730637 T PL11730637 T PL 11730637T PL 2590974 T3 PL2590974 T3 PL 2590974T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrido
- tetrahydro
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36158910P | 2010-07-06 | 2010-07-06 | |
| PCT/EP2011/061393 WO2012004299A1 (en) | 2010-07-06 | 2011-07-06 | Tetrahydro-pyrido-pyrimidine derivatives |
| EP11730637.3A EP2590974B1 (en) | 2010-07-06 | 2011-07-06 | Tetrahydro-pyrido-pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2590974T3 true PL2590974T3 (pl) | 2014-10-31 |
Family
ID=44532774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11730637T PL2590974T3 (pl) | 2010-07-06 | 2011-07-06 | Pochodne tetrahydropirydo-pirymidyny |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US8653092B2 (pl) |
| EP (1) | EP2590974B1 (pl) |
| JP (1) | JP5770842B2 (pl) |
| KR (1) | KR101560066B1 (pl) |
| CN (1) | CN102971317B (pl) |
| AR (3) | AR084970A1 (pl) |
| AU (1) | AU2011275777C1 (pl) |
| BR (1) | BR112013000275B1 (pl) |
| CA (1) | CA2802132C (pl) |
| CL (1) | CL2013000033A1 (pl) |
| CO (1) | CO6670566A2 (pl) |
| CR (1) | CR20130004A (pl) |
| DK (1) | DK2590974T3 (pl) |
| DO (1) | DOP2013000027A (pl) |
| EA (1) | EA024123B1 (pl) |
| EC (1) | ECSP13012420A (pl) |
| ES (1) | ES2494718T3 (pl) |
| GT (1) | GT201300009A (pl) |
| HR (1) | HRP20140778T1 (pl) |
| IL (1) | IL223795A (pl) |
| JO (1) | JO2939B1 (pl) |
| MA (1) | MA34361B1 (pl) |
| MX (1) | MX2012015088A (pl) |
| MY (1) | MY166026A (pl) |
| NI (1) | NI201300002A (pl) |
| NZ (1) | NZ604302A (pl) |
| PE (1) | PE20130650A1 (pl) |
| PH (1) | PH12013500031A1 (pl) |
| PL (1) | PL2590974T3 (pl) |
| PT (1) | PT2590974E (pl) |
| RS (1) | RS53490B1 (pl) |
| SG (1) | SG186187A1 (pl) |
| SI (1) | SI2590974T1 (pl) |
| TN (1) | TN2012000578A1 (pl) |
| TW (1) | TWI534145B (pl) |
| UA (1) | UA112517C2 (pl) |
| UY (1) | UY33486A (pl) |
| WO (1) | WO2012004299A1 (pl) |
| ZA (1) | ZA201209117B (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| CA2840315A1 (en) | 2011-06-27 | 2013-01-03 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| PT2790705T (pt) * | 2011-12-15 | 2018-01-24 | Novartis Ag | Utilização de inibidores da atividade ou função de pi3k |
| PL2794600T3 (pl) | 2011-12-22 | 2018-06-29 | Novartis Ag | Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów |
| EP2916868B1 (en) | 2012-11-08 | 2022-05-11 | Rhizen Pharmaceuticals S.A. | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| KR20150082613A (ko) * | 2012-11-16 | 2015-07-15 | 머크 샤프 앤드 돔 코포레이션 | 인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 |
| KR20150084992A (ko) | 2012-11-16 | 2015-07-22 | 머크 샤프 앤드 돔 코포레이션 | 인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 |
| EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015162584A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| JP6462155B2 (ja) * | 2015-05-04 | 2019-01-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 |
| HK1257295A1 (zh) | 2015-12-04 | 2019-10-18 | Novartis Ag | 用於免疫肿瘤学的组合物和方法 |
| HRP20200916T1 (hr) | 2016-02-10 | 2020-09-18 | Novartis Ag | Uporaba inhibitora aktivnosti ili funkcije pi3k za liječenje primarnog sjörgen-ovog sindroma |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| WO2019036641A1 (en) | 2017-08-17 | 2019-02-21 | Board Of Regents, The University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| WO2019178590A1 (en) | 2018-03-16 | 2019-09-19 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of atr kinase |
| CN114315826B (zh) * | 2021-11-30 | 2023-05-16 | 西安交通大学 | 一种吡啶并嘧啶类化合物及其应用 |
| KR20230160977A (ko) | 2022-05-17 | 2023-11-27 | 에이치앤오바이오시스(주) | 항암 치료에 사용되는 5종 이상의 생약 추출물 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1197466B (de) | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (pl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5300645A (en) | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
| JP2000512990A (ja) | 1996-06-24 | 2000-10-03 | ファイザー・インク | 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体 |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
| CA2350189A1 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| SG159378A1 (en) | 2000-11-07 | 2010-03-30 | Novartis Ag | Indolylmaleimide derivatives as protein kinase c inhibitors |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| KR20050084224A (ko) | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
| US7414045B2 (en) | 2002-12-27 | 2008-08-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| BRPI0506817A (pt) | 2004-01-12 | 2007-05-29 | Cytopia Res Pty Ltd | inibidores seletivos de quinase |
| EP1713807A1 (en) * | 2004-01-23 | 2006-10-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1761528B1 (en) | 2004-06-11 | 2008-01-09 | Japan Tobacco, Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer |
| US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7745451B2 (en) * | 2005-05-04 | 2010-06-29 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US8653091B2 (en) * | 2007-04-02 | 2014-02-18 | Evotec Ag | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| JP5498374B2 (ja) * | 2007-04-17 | 2014-05-21 | エボテック・アーゲー | ２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用 |
| WO2009047255A1 (en) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| ES2553340T3 (es) | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| US20120028940A1 (en) | 2008-09-16 | 2012-02-02 | Merck Sharp & Dohme Corp. | Functionally selective azanitrile alpha-2c adrenoreceptor agonists |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
| JP2010105951A (ja) | 2008-10-29 | 2010-05-13 | Dainippon Sumitomo Pharma Co Ltd | ６−アルキル置換テトラヒドロピリド［４，３−ｄ］ピリミジン誘導体 |
| TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| WO2010120991A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses |
| US20100280067A1 (en) | 2009-04-30 | 2010-11-04 | Pakala Kumara Savithru Sarma | Inhibitors of acetyl-coa carboxylase |
| ES2659725T3 (es) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
| US8492392B2 (en) | 2009-05-27 | 2013-07-23 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011085129A2 (en) | 2010-01-06 | 2011-07-14 | Errico Joseph P | Methods and compositions of targeted drug development |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| CA2798325A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| PT2790705T (pt) | 2011-12-15 | 2018-01-24 | Novartis Ag | Utilização de inibidores da atividade ou função de pi3k |
-
2011
- 2011-06-07 UA UAA201213598A patent/UA112517C2/uk unknown
- 2011-07-01 US US13/175,050 patent/US8653092B2/en active Active
- 2011-07-04 AR ARP110102390A patent/AR084970A1/es not_active Application Discontinuation
- 2011-07-05 JO JO2011215A patent/JO2939B1/en active
- 2011-07-05 TW TW100123736A patent/TWI534145B/zh active
- 2011-07-06 EA EA201291317A patent/EA024123B1/ru not_active IP Right Cessation
- 2011-07-06 DK DK11730637.3T patent/DK2590974T3/da active
- 2011-07-06 RS RS20140427A patent/RS53490B1/sr unknown
- 2011-07-06 NZ NZ604302A patent/NZ604302A/en unknown
- 2011-07-06 PH PH1/2013/500031A patent/PH12013500031A1/en unknown
- 2011-07-06 PL PL11730637T patent/PL2590974T3/pl unknown
- 2011-07-06 MY MYPI2012005385A patent/MY166026A/en unknown
- 2011-07-06 MX MX2012015088A patent/MX2012015088A/es active IP Right Grant
- 2011-07-06 HR HRP20140778AT patent/HRP20140778T1/hr unknown
- 2011-07-06 UY UY0001033486A patent/UY33486A/es active IP Right Grant
- 2011-07-06 SG SG2012089496A patent/SG186187A1/en unknown
- 2011-07-06 CN CN201180033521.1A patent/CN102971317B/zh active Active
- 2011-07-06 MA MA35527A patent/MA34361B1/fr unknown
- 2011-07-06 PE PE2013000017A patent/PE20130650A1/es active IP Right Grant
- 2011-07-06 KR KR1020137000230A patent/KR101560066B1/ko active Active
- 2011-07-06 EP EP11730637.3A patent/EP2590974B1/en active Active
- 2011-07-06 CA CA2802132A patent/CA2802132C/en active Active
- 2011-07-06 BR BR112013000275-1A patent/BR112013000275B1/pt active IP Right Grant
- 2011-07-06 SI SI201130220T patent/SI2590974T1/sl unknown
- 2011-07-06 JP JP2013517375A patent/JP5770842B2/ja active Active
- 2011-07-06 WO PCT/EP2011/061393 patent/WO2012004299A1/en not_active Ceased
- 2011-07-06 PT PT117306373T patent/PT2590974E/pt unknown
- 2011-07-06 ES ES11730637.3T patent/ES2494718T3/es active Active
- 2011-07-06 AU AU2011275777A patent/AU2011275777C1/en active Active
-
2012
- 2012-12-03 ZA ZA2012/09117A patent/ZA201209117B/en unknown
- 2012-12-06 TN TNP2012000578A patent/TN2012000578A1/en unknown
- 2012-12-20 IL IL223795A patent/IL223795A/en active IP Right Grant
-
2013
- 2013-01-03 CO CO13001273A patent/CO6670566A2/es active IP Right Grant
- 2013-01-04 GT GT201300009A patent/GT201300009A/es unknown
- 2013-01-04 CL CL2013000033A patent/CL2013000033A1/es unknown
- 2013-01-07 CR CR20130004A patent/CR20130004A/es unknown
- 2013-01-07 NI NI201300002A patent/NI201300002A/es unknown
- 2013-02-01 DO DO2013000027A patent/DOP2013000027A/es unknown
- 2013-02-04 EC ECSP13012420 patent/ECSP13012420A/es unknown
-
2014
- 2014-01-09 US US14/151,796 patent/US9499536B2/en active Active
-
2016
- 2016-10-05 US US15/285,614 patent/US20170022199A1/en not_active Abandoned
-
2017
- 2017-06-05 US US15/613,560 patent/US20170267678A1/en not_active Abandoned
-
2018
- 2018-05-30 US US15/993,051 patent/US20180265509A1/en not_active Abandoned
- 2018-10-17 US US16/163,106 patent/US20190040061A1/en not_active Abandoned
-
2019
- 2019-03-28 US US16/367,525 patent/US20190218217A1/en not_active Abandoned
- 2019-08-07 AR ARP190102244A patent/AR115927A2/es unknown
-
2020
- 2020-05-12 AR ARP200101358A patent/AR118919A2/es unknown
- 2020-06-30 US US16/916,168 patent/US20200392132A1/en not_active Abandoned
-
2021
- 2021-08-11 US US17/399,090 patent/US20220267318A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,244 patent/US20250059181A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222646A0 (en) | N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives | |
| DK3342786T3 (en) | Anti-dll3-antistof | |
| AP3107A (en) | 5-Alkynyl-pyrimidines | |
| ZA201209117B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| EP2566479A4 (en) | AZA-INDAZOLES | |
| EP2640189A4 (en) | 3-deutero-pomalidomide | |
| ZA201300032B (en) | Tetrahydrocarboline derivative | |
| DK3466977T3 (en) | Anti-vla-4-antistoffer | |
| EP2641891A4 (en) | PKC ACTIVATOR- | |
| GB201005467D0 (en) | Dazzlers | |
| GB2490849B (en) | Di-aspirin derivatives | |
| ZA201303887B (en) | 2-carboxamide-4-piperazinyl-benzofuran derivative | |
| SI2628733T1 (sl) | Derivati acilbenzena | |
| HUP1000243A2 (en) | 8-hidroxy-quinoline derivatives | |
| ZA201209248B (en) | Amido-tropane derivatives | |
| IL220983A0 (en) | 2-aldoximino-5-fluoropyrimidine derivatives | |
| AU4932P (en) | FlatwaxpinkGL Chamelaucium uncinatum | |
| AU4822P (en) | FlatwaxwhiteGL Chamelaucium uncinatum | |
| AU4536P (en) | TB01 Tibouchina urvilleana | |
| AU4931P (en) | FlatwaxDarkGL Chamelaucium uncinatum | |
| AU4937P (en) | FlatinsulGL Myoporum insulare | |
| GB201000020D0 (en) | Velcrose | |
| GB201000203D0 (en) | Formits | |
| GB201000066D0 (en) | 1Velcrose | |
| GB201000706D0 (en) | Kilthanger |